Lazertinib
Pre-clinicalUNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Feb 1, 2023 → Dec 31, 2025
NCT ID
NCT05716672About Lazertinib
Lazertinib is a pre-clinical stage product being developed by Yuhan for Non-small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05716672. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
3
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05716672 | Pre-clinical | UNKNOWN |
| NCT05338619 | Phase 2 | UNKNOWN |
| NCT04075396 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer